Tibet Rhodiola Pharmaceutical Holding Co (SHG:600211) — Market Cap & Net Worth
Market Cap & Net Worth: Tibet Rhodiola Pharmaceutical Holding Co (600211)
Tibet Rhodiola Pharmaceutical Holding Co (SHG:600211) has a market capitalization of $1.79 Billion (CN¥12.22 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #6537 globally and #1323 in its home market, demonstrating a -0.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tibet Rhodiola Pharmaceutical Holding Co's stock price CN¥37.91 by its total outstanding shares 322319196 (322.32 Million). See Tibet Rhodiola Pharmaceutical Holding Co (600211) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Tibet Rhodiola Pharmaceutical Holding Co Market Cap History: 2015 to 2026
Tibet Rhodiola Pharmaceutical Holding Co's market capitalization history from 2015 to 2026. Data shows growth from $1.33 Billion to $1.79 Billion (4.35% CAGR).
Tibet Rhodiola Pharmaceutical Holding Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tibet Rhodiola Pharmaceutical Holding Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.68x
Tibet Rhodiola Pharmaceutical Holding Co's market cap is 0.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.14x
Tibet Rhodiola Pharmaceutical Holding Co's market cap is 2.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.65 Billion | $796.81 Million | $198.29 Million | 2.08x | 8.35x |
| 2017 | $1.03 Billion | $915.63 Million | $229.65 Million | 1.13x | 4.50x |
| 2018 | $917.23 Million | $1.03 Billion | $215.61 Million | 0.89x | 4.25x |
| 2019 | $1.00 Billion | $1.26 Billion | $312.32 Million | 0.80x | 3.22x |
| 2020 | $3.08 Billion | $1.37 Billion | $418.10 Million | 2.24x | 7.36x |
| 2021 | $2.42 Billion | $2.14 Billion | $208.94 Million | 1.13x | 11.58x |
| 2022 | $1.67 Billion | $2.55 Billion | $369.84 Million | 0.66x | 4.53x |
| 2023 | $2.30 Billion | $3.13 Billion | $800.91 Million | 0.73x | 2.87x |
| 2024 | $1.74 Billion | $2.81 Billion | $1.05 Billion | 0.62x | 1.66x |
| 2025 | $2.01 Billion | $2.95 Billion | $937.93 Million | 0.68x | 2.14x |
Competitor Companies of 600211 by Market Capitalization
Companies near Tibet Rhodiola Pharmaceutical Holding Co in the global market cap rankings as of August 7, 2026.
Key companies related to Tibet Rhodiola Pharmaceutical Holding Co by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #556 globally with a market cap of $48.64 Billion USD ( CN¥332.41 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #625 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.91 |
| #556 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $48.64 Billion | CN¥52.11 |
| #625 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Tibet Rhodiola Pharmaceutical Holding Co Historical Marketcap From 2015 to 2026
Between 2015 and today, Tibet Rhodiola Pharmaceutical Holding Co's market cap moved from $1.33 Billion to $ 1.79 Billion, with a yearly change of 4.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.79 Billion | -10.90% |
| 2025 | CN¥2.01 Billion | +15.19% |
| 2024 | CN¥1.74 Billion | -24.30% |
| 2023 | CN¥2.30 Billion | +37.46% |
| 2022 | CN¥1.67 Billion | -30.77% |
| 2021 | CN¥2.42 Billion | -21.35% |
| 2020 | CN¥3.08 Billion | +206.24% |
| 2019 | CN¥1.00 Billion | +9.48% |
| 2018 | CN¥917.23 Million | -11.28% |
| 2017 | CN¥1.03 Billion | -37.53% |
| 2016 | CN¥1.65 Billion | +24.21% |
| 2015 | CN¥1.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 7th, 2026 the market cap of Tibet Rhodiola Pharmaceutical Holding Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.79 Billion USD |
| MoneyControl | $1.79 Billion USD |
| MarketWatch | $1.79 Billion USD |
| marketcap.company | $1.79 Billion USD |
| Reuters | $1.79 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more